EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	882	514/375.ccls.	US-PGPUB; USPAT	OR	ON	2007/09/19 14:06
L2	1497	514/381.ccls.	US-PGPUB; USPAT	OR	ON	2007/09/19 14:06
L3	1128	514/411.ccls.	US-PGPUB; USPAT	OR	ON	2007/09/19 14:06
L4	605	514/418.ccls.	US-PGPUB; USPAT	OR	ON	2007/09/19 14:06
L5	1652	514/419.ccls.	US-PGPUB; USPAT	OR	ON	2007/09/19 14:06
L6	232	514/429.ccls.	US-PGPUB; USPAT	OR	ON	2007/09/19 14:06
L7	271	514/431.ccls.	US-PGPUB; USPAT	OR	ON	2007/09/19 14:07
L8	417	514/448.ccls.	US-PGPUB; USPAT	OR	ON	2007/09/19 14:07
L9	792	514/569.ccls.	US-PGPUB; USPAT	OR	ON	2007/09/19 14:07
L10	1111	514/570.ccls.	US-PGPUB; USPAT	OR	ON	2007/09/19 14:07
L11	7750	L1 OR L2 OR L3 OR L4 OR L5 OR L6 OR L7 OR L8 OR L9 OR L10	US-PGPUB; USPAT	OR	ON	2007/09/19 14:07
L12	1526	L11 AND ALZHEIMER	US-PGPUB; USPAT	OR	ON	2007/09/19 14:08
L13	265	L12 AND AMYLOID	US-PGPUB; USPAT	OR	ON	2007/09/19 14:08

STN Search (Reg/Caplus) - Claim 42

L1 STRUCTURE UPLOADED

=> D
L1 HAS NO ANSWERS
L1 STR







G1 CO2H,COOH,[@1],[@2]
G2 Cb,Ak

Structure attributes must be viewed using STN Express query preparation.

=> S L1
SAMPLE SEARCH INITIATED 14:57:13 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 19 TO ITERATE

100.0% PROCESSED 19 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 119 TO 641
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> S L1 FULL
FULL SEARCH INITIATED 14:57:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED 455 TO ITERATE

100.0% PROCESSED 455 ITERATIONS 7 ANSWERS
SEARCH TIME: 00.00.01

L3 7 SEA SSS FUL L1

=> FIL CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.10	172.31

FILE 'CAPLUS' ENTERED AT 14:57:24 ON 19 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 19 Sep 2007 VOL 147 ISS 13
FILE LAST UPDATED: 18 Sep 2007 (20070918/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> S L3
L4          23 L3

=> S L4 AND ALZHEIMER
         46782 ALZHEIMER
L5           8 L4 AND ALZHEIMER

=> D IBIB ABS HITSTR 1-8
```

L5 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:384840 CAPLUS
DOCUMENT NUMBER: 146:365795
TITLE: Combination therapy comprising Aβ42 lowering agent and hormonal modulating agent
INVENTOR(S): Hobden, Adrian; Laslie, Wayne
PATENT ASSIGNEE(S): Myriad Genetics, Incorporated, USA
SOURCE: U.S. Pat. Appl. Publ., 24pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2007078114	A1	20070405	US 2006-470190		20060905
PRIORITY APPLN. INFO.:			US 2005-713369P	P	20050902

OTHER SOURCE(S): MARPAT 146:365795
AB The invention relates to combinations of one or more Aβ42 lowering agents and one or more hormonal modulating agent for treatment of alzheimer's disease and other diseases. Thus, tablet was prepared containing (R)-2-(2-Fluoro-4-biphenylyl)propionic acid 400 mg, microcryst. cellulose 392 mg, colloidal silicon dioxide 4 mg, magnesium stearate 4 mg, and prednisone 25 mg.
IT 150972-50-2 730977-79-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy comprising Aβ42 lowering agent and hormonal modulating agent)
RN 150972-50-2 CAPLUS
CN [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-α,α-dimethyl- (CA INDEX NAME)



RN 730977-79-4 CAPLUS
CN 2H-Tetrazole, 5-[1-(2-fluoro[1,1'-biphenyl]-4-yl)-1-methylethyl]- (CA INDEX NAME)

L5 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L5 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:63637 CAPLUS
DOCUMENT NUMBER: 146:135610
TITLE: Methods of treating overactive bladder and urinary incontinence
INVENTOR(S): Laughlin, Mark
PATENT ASSIGNEE(S): Myriad Genetics, Incorporated, USA
SOURCE: U.S. Pat. Appl. Publ., 16pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2007015832	A1	20070118	US 2006-487177		20060714
PRIORITY APPLN. INFO.:			US 2005-699727P	P	20050714

OTHER SOURCE(S): MARPAT 146:135610
AB The invention relates to methods of treating or slowing the onset of overactive bladder and urinary incontinence, or a symptom thereof selected from urinary frequency, urinary urgency, nocturia, or enuresis. In one aspect, the method comprises identifying and administering to a subject in need of treatment a therapeutically effective amount of an Aβ42 lowering agent such as (R)-2-(2-fluoro-4-biphenyl)propionic acid.
IT 150972-50-2 730977-79-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods of treating overactive bladder and urinary incontinence using Aβ42 lowering agents such as (fluorobiphenyl)propionic acid and combination with other agents in relation to Alzheimer's disease)
RN 150972-50-2 CAPLUS
CN [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-α,α-dimethyl- (CA INDEX NAME)



RN 730977-79-4 CAPLUS
CN 2H-Tetrazole, 5-[1-(2-fluoro[1,1'-biphenyl]-4-yl)-1-methylethyl]- (CA INDEX NAME)

L5 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:232875 CAPLUS
DOCUMENT NUMBER: 144:403783
TITLE: The geminal dimethyl analogue of Flurbiprofen as a novel Aβ42 inhibitor and potential Alzheimer's disease modifying agent
AUTHOR(S): Stock, Nicholas; Munoz, Benito; Wrigley, Jonathan D. J.; Shearman, Mark S.; Beher, Dirk; Peachey, James; Williamson, Toni L.; Bain, Gretchen; Chen, Weichao; Jiang, Xiaohui; St-Jacques, Rene; Prasit, Peppi
CORPORATE SOURCE: Department of Chemistry, Merck Research Laboratories, San Diego, CA, 92121, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(8), 2219-2223
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The subtle modification of a selection of Aβ42 inhibiting non-steroidal anti-inflammatory drugs (NSAIDs), through synthesis of the geminal di-Me analogs, was anticipated to ablate their cyclooxygenase activity while maintaining Aβ42 inhibition. Methylflurbiprofen I exhibited similar in vitro Aβ42 inhibition to its parent NSAID Flurbiprofen and was further evaluated in the Tg2576 mouse model of Alzheimer's disease and an animal model of gastro-intestinal (GI) impairment, but proved unviable for further clin. development.
IT 150972-50-2P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(geminal di-Me analog of Flurbiprofen as Aβ42 inhibitor and potential Alzheimer's disease modifying agent)
RN 150972-50-2 CAPLUS
CN [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-α,α-dimethyl- (CA INDEX NAME)

L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:167837 CAPLUS
DOCUMENT NUMBER: 144:239971
TITLE: Pharmaceutical composition and method for treating neurodegenerative disorders
INVENTOR(S): Hobden, Adrian
PATENT ASSIGNEE(S): Myriad Genetics, Inc., USA
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006020850	A2	20060223	WO 2005-US28714	20050811
WO 2006020850	A3	20060504		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-600447P P 20040811

AB The invention provides compns. and methods for treating neurodegenerative disorders. The method of the invention involves administering to an individual in need of treatment a composition having an acetylcholine esterase inhibitor and another therapeutic agent. The methods and compns. of the invention are useful for treating and preventing neurodegenerative disorders like Alzheimer's disease, dementia, and mild cognitive impairment.
IT 150972-50-2 730977-79-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical composition and method for treating neurodegenerative disorders)
RN 150972-50-2 CAPLUS
CN [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-α,α-dimethyl- (CA INDEX NAME)



L5 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 730977-79-4 CAPLUS
CN 2H-Tetrazole, 5-[1-(2-fluoro[1,1'-biphenyl]-4-yl)-1-methylethyl]- (CA INDEX NAME)



L5 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:164779 CAPLUS
DOCUMENT NUMBER: 144:239954
TITLE: Pharmaceutical compositions acetylcholine esterase inhibitors for treating neurodegenerative disorders
INVENTOR(S): Hobden, Adrian
PATENT ASSIGNEE(S): Myriad Genetics, Inc., USA
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006020852	A2	20060223	WO 2005-US28716	20050811
WO 2006020852	A3	20060526		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-600600P P 20040811

AB The invention provides compns. and methods for treating neurodegenerative disorders. The method of the invention involves administering to an individual in need of treatment an acetylcholine esterase inhibitor in combination with another therapeutic agent. The methods and compns. of the invention are useful for treating and preventing neurodegenerative disorders like Alzheimer's disease, dementia, and mild cognitive impairment. A tablet contained (R)-2-(2-fluoro-4-biphenylyl)propionic acid 400, microcryst. cellulose 392, colloidal silicon dioxide 4, magnesium stearate 4, and galantamine hydrobromide 16 mg.

IT 150972-50-2 730977-79-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. acetylcholine esterase inhibitors for treating neurodegenerative disorders)

RN 150972-50-2 CAPLUS
CN [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-α,α-dimethyl- (CA INDEX NAME)

L5 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 730977-79-4 CAPLUS
CN 2H-Tetrazole, 5-[1-(2-fluoro[1,1'-biphenyl]-4-yl)-1-methylethyl]- (CA INDEX NAME)



L5 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:164727 CAPLUS
DOCUMENT NUMBER: 144:260786
TITLE: Pharmaceutical compositions containing acetylcholine esterase inhibitors for treating neurodegenerative disorders
INVENTOR(S): Hobden, Adrian
PATENT ASSIGNEE(S): Myriad Genetics, Inc., USA
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006020853	A2	20060223	WO 2005-US28717	20050811
WO 2006020853	A3	20060526		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-600470P P 20040811

AB The invention provides compns. and methods for treating neurodegenerative disorders. The method of the invention involves administering to an individual in need of treatment a composition having an acetylcholine esterase
inhibitor and another therapeutic agent. The methods and compns. of the invention are useful for treating and preventing neurodegenerative disorders like Alzheimer's disease, dementia, and mild cognitive impairment. A tablet contained (R)-2-(2-fluoro-4-biphenylyl)propionic acid 400, microcryst. cellulose 392, colloidal silicon dioxide 4, magnesium stearate 4, and donepezil hydrochloride 16 mg.

IT 150972-50-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical composition and method for treating neurodegenerative disorders)

RN 150972-50-2 CAPLUS
CN [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-α,α-dimethyl- (CA INDEX NAME)

L5 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L5 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1075559 CAPLUS
DOCUMENT NUMBER: 143:367205
TITLE: Preparation of compounds, especially indoles and biphenyls, useful for treating neurodegenerative disorders, particularly Alzheimer's disease and other amyloid β42 protein-related disorders
INVENTOR(S): Slade, Rachel M.; Weiner, Warren S.; Delmar, Eric G.; Klimova, Yevgeniya I.; Trovato, Richard
PATENT ASSIGNEE(S): Myriad Genetics, Inc., USA
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005092062	A2	20051006	WO 2005-US9595	20050321
WO 2005092062	A3	20060803		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-554571P P 20040319
US 2004-590259P P 20040722

OTHER SOURCE(S): CASREACT 143:367205; MARPAT 143:367205
GI

L5 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB Title compds., e.g. I, [L = C:O, CH2; R1, R2, R4-R7, R9 = independently H, OH, halo, halo/alkyl, etc.; R3 = CHF2, CF3, OCF3, OCHF2; R8 = H, halo, alkoxy, etc.; R10 = alkenylene-CO2H, alkylene-CO2H, alkynylene-CO2H; R11 = alkyl; and their pharmaceutically acceptable salts] were prepared as lowering cellular amyloid β42 protein (Aβ42) production and/or secretion agents useful for the therapeutic treatment and prevention of neurodegenerative disorders such as Alzheimer's disease, mild cognitive impairment, dementia etc. For example, II was prepared in 3 steps from [5-tert-butyl-2-methyl-1H-indol-3-yl]acetic acid and 4-trifluoromethoxybenzoyl chloride. Selected I were found to not significantly inhibit COX-1 and COX-2 at 100 μM. In amyloid precursor protein assays, selected I lowered Aβ42 levels by at least 50% of DMSO control at concentration ranging from 30 to 80 μM.
IT 150972-50-2P, 2-(2-Fluorobiphenyl-4-yl)-2-methylpropanoic acid
866235-88-3P, 2-(2-Fluorobiphenyl-4-yl)-2-methylbutyric acid
866235-92-9P, 2-Ethyl-2-(2-fluorobiphenyl-4-yl)butyric acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of compds., especially indoles and biphenyls, useful for treating neurodegenerative disorders)
RN 150972-50-2 CAPLUS
CN [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-α,α-dimethyl- (CA INDEX NAME)

L5 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 866235-88-3 CAPLUS
CN [1,1'-Biphenyl]-4-acetic acid, α-ethyl-2-fluoro-α-methyl- (CA INDEX NAME)



RN 866235-92-9 CAPLUS
CN [1,1'-Biphenyl]-4-acetic acid, α,α-diethyl-2-fluoro- (CA INDEX NAME)



L5 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:633474 CAPLUS
DOCUMENT NUMBER: 141:162386
TITLE: Anti-Alzheimer compositions containing geminally di-substituted NSAID derivatives
INVENTOR(S): Munoz, Benito; Prasit, Petpiboon; Stock, Nicholas Simon
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004064771	A2	20040805	WO 2004-US424	20040109
WO 2004064771	A3	20041223		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI

AU 2004206796	A1	20040805	AU 2004-206796	20040109
CA 2512704	A1	20040805	CA 2004-2512704	20040109
EP 1587798	A2	20051026	EP 2004-701220	20040109

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2006517925	T	20060803	JP 2006-500855	20040109
US 2006063937	A1	20060323	US 2005-540601	20050623

PRIORITY APPLN. INFO.: US 2003-439847P P 20030114
US 2003-439965P P 20030114
WO 2004-US424 W 20040109

OTHER SOURCE(S): MARPAT 141:162386
GI



I

AB The present invention encompasses compds. of Formula I or pharmaceutically acceptable salts thereof, wherein A is the base mol. of a propionic acid or acetic acid NSAID, or a derivative thereof; X is -CO2H, 1H-tetrazol-5-yl or 2H-tetrazol-5-yl and R1 and R2 are each independently selected from the group consisting of C1-6 alkyl and C3-6 cycloalkyl; R3 is independently selected from fluoro, chloro, bromo, NH2, Me, Et, methoxy and CF3. This invention also relates to the pharmaceutical composition comprising said compds. and methods of using said compds. The compds. of the present invention lower the level of Aβ42 and are therefore useful for

L5 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
preventing, delaying or reversing the progression of Alzheimer's Disease.
IT 150972-50-2P 730977-79-4P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn of geminally di-substituted NSAID derivs. as anti-Alzheimer agents)
RN 150972-50-2 CAPLUS
CN [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-α,α-dimethyl- (CA INDEX NAME)



RN 730977-79-4 CAPLUS
CN 2H-Tetrazole, 5-[1-(2-fluoro[1,1'-biphenyl]-4-yl)-1-methylethyl]- (CA INDEX NAME)